PDGF-BB Exhibited Therapeutic Effects on Rat Model of Bisphosphonate-related Osteonecrosis of the Jaw by Enhancing Angiogenesis and Osteogenesis
Overview
Authors
Affiliations
The mechanism and effective treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) are still uncertain. Our previous study revealed that zoledronate (ZOL) preferentially inhibited osteoclasts formation and platelet-derived growth factor-BB (PDGF-BB) secretion, causing suppression of angiogenesis and osteogenesis in vitro. The present study aimed to elucidate whether PDGF-BB had therapeutic effects on rat model of BRONJ by enhancing angiogenesis and angiogenesis. Firstly, rat model of BRONJ was established by ZOL and dexamethasone administration, followed by teeth extraction. The occurrence of BRONJ was confirmed and detected dead bone formation by maxillae examination, micro-CT scan and HE staining (10/10). Compared to control rats (0/10), both angiogenesis and mature bone formation were suppressed in BRONJ-like rats, evidenced by enzyme-linked immunosorbent assay (ELISA) for VEGF (P < 0.01), immunohistochemistry of CD31 (P < 0.05) and OCN (P < 0.01). Moreover, in the early stage of bone healing, the number of preosteoclasts (P < 0.001) and PDGF-BB secretion (P < 0.05) were significantly decreased in bisphosphonates-treated rats, along with the declined numbers of microvessels (P < 0.05) and osteoblasts (P < 0.05). In vitro study, CCK8 assay, alizarin red S staining and western blot assay showed that mandible-derived bone marrow mesenchymal stem cells (BMMSCs) in BRONJ-like rats presented suppressed functions of proliferation, osteogenesis and angiogenesis. Interestingly, recombinant PDGF-BB was able to rescue the impaired functions of BMMSCs derived from BRONJ-like rats at more than 10 ng/ml. Then fibrin sealant with or without recombinant PDGF-BB were tamped into the socket after debridement in BRONJ rats. After 8 weeks, fibrin sealant containing PDGF-BB showed significant therapeutic effects on BRONJ-like rats (bone healing: 8/10 vs 3/10, P < 0.05) with enhancing microvessels and mature bone formation. Our study suggested that the inhibition of angiogenesis and osteogenesis, the potential mechanisms of BRONJ, might partly result from suppression of PDGF-BB secretion in the early stage of bone healing. PDGF-BB local treatment after debridement might avail the healing of BRONJ by increasing angiogenesis and osteogenesis.
Li Z, Li Q, Ahmad A, Yue Z, Wang H, Wu G Front Bioeng Biotechnol. 2024; 12:1441053.
PMID: 39380894 PMC: 11458455. DOI: 10.3389/fbioe.2024.1441053.
Bennardo F, Barone S, Antonelli A, Giudice A Periodontol 2000. 2024; 97(1):287-307.
PMID: 39345044 PMC: 11808450. DOI: 10.1111/prd.12608.
Sakamoto Y, Sawada S, Kojima Y Cureus. 2024; 16(5):e60223.
PMID: 38868238 PMC: 11167574. DOI: 10.7759/cureus.60223.
Heitzer M, Winnand P, Ooms M, Magnuska Z, Kiessling F, Buhl E Int J Mol Sci. 2024; 25(8).
PMID: 38673796 PMC: 11049800. DOI: 10.3390/ijms25084210.
Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
Bassan Marinho Maciel G, Maciel R, Linhares Ferrazzo K, Cademartori Danesi C J Mol Med (Berl). 2024; 102(3):353-364.
PMID: 38302741 DOI: 10.1007/s00109-024-02425-9.